galantamine (Reminyl, Razadyne, Nivalin)

From Aaushi
Jump to navigation Jump to search

Introduction

Tradenames: Reminyl, Nivalin. (galantamine hydrobromide) Reminyl name change to Razadyne*[14]

* 3 reported cases of Amaryl (glimepiride) subsitution for Reminyl Extracted from the bulbs of the daffodil, Narcissus pseudonarcissus.

Indications

See galantamine clinical trials

Contraindications

Dosage

  • start 4 mg PO BID for at least 4 weeks
  • increase to 8 mg PO BID
  • max: 12-16 mg BID
  • Razadyne ER, QD dosing

Tabs: 4, 8 & 12 mg

Solution: (oral) 4 mg/mL. Razadyne ER: 8, 16, 24 mg

Pharmacokinetics

elimination via kidney

1/2life = 5-7 hours

protein binding = 18 %

Adverse effects

Drug interactions

Mechanism of action

Notes

generic available

More general terms

More specific terms

Additional terms

References

  1. Journal Watch 21(2):18, 2001 Wilcock GK et al, Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 321:1445, 2000 PMID: https://www.ncbi.nlm.nih.gov/pubmed/11110737
  2. Prescriber's Letter 8(5):26 2001
  3. http://www.nivalin.com
  4. 4.0 4.1 4.2 Janssen Pharmaceuticals, package insert
  5. Role of cholinergic therapy in treatment of Alzheimer's disease & other dementias, Farlow, M et al, 2001
  6. 6.0 6.1 Small G. In: Intensive Course in Geriatric Medicine & Board Review, Marina Del Ray, CA, Sept 12-15, 2001
  7. 7.0 7.1 7.2 Raskind MA et al, Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 54:2261, 2000 {clinical trial} PMID: https://www.ncbi.nlm.nih.gov/pubmed/10881250
  8. Physician's Desk Reference (PDR) 56th edition, Medical Economics, 2002
  9. 9.0 9.1 9.2 Journal Watch 22(11):89, 2002 Erkinjuntti T et al, Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 359:1283, 2002 PMID: https://www.ncbi.nlm.nih.gov/pubmed/11965273
    Schneider LS, Galantamine for vascular dementia: some answers, some questions. Lancet 359:1265, 2002 PMID: https://www.ncbi.nlm.nih.gov/pubmed/11965268
  10. Olin J & Schneider L, Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. (3):CD001747, 2002 PMID: https://www.ncbi.nlm.nih.gov/pubmed/12137632
  11. 11.0 11.1 Wilcock GK et al Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ. 2000 Dec 9;321(7274):1445-9. Erratum in: BMJ 2001 Feb 17; 322(7283):405. PMID: https://www.ncbi.nlm.nih.gov/pubmed/11110737
  12. 12.0 12.1 12.2 Arias E, Ales E, Gabilan NH, Cano-Abad MF, Villarroya M, Garcia AG, Lopez MG. Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors. Neuropharmacology. 2004 Jan;46(1):103-14. PMID: https://www.ncbi.nlm.nih.gov/pubmed/14654102
  13. 13.0 13.1 FDA Medwatch http://www.fda.gov/medwatch/SAFETY/2005/safety05.htm#Reminyl
  14. 14.0 14.1 Prescriber's Letter 12(5): 2005 Reminyl Name Changed to Razadyne Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210502&pb=PRL (subscription needed) http://www.prescribersletter.com
  15. Department of Veterans Affairs, VA National Formulary
  16. Auchis AP et al, Galantamine treatment of vascular dementia: A randomized trial. Neurology 2007, 69:448 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17664404
  17. Prescriber's Letter 16(10): 2009 Anticipated Availability of First-Time Generics Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=251011&pb=PRL (subscription needed) http://www.prescribersletter.com
  18. Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015
  19. 19.0 19.1 Masurkar PP, Chatterjee S, Sherer JT et al. Risk of Serious Adverse Events Associated With Individual Cholinesterase Inhibitors Use in Older Adults With Dementia: A Population-Based Cohort Study. Drugs Aging 2022. June 6 PMID: https://www.ncbi.nlm.nih.gov/pubmed/35666463 https://link.springer.com/article/10.1007/s40266-022-00944-z
  20. Highlights of Prescribing Information RAZADYNE (galantamine hydrobromide) tablets/capsules/solution, for oral use https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021615s021lbl.pdf

Database